How big is Innoviva, Inc.?

As of Jun 18, Innoviva, Inc. has a market capitalization of $2.03 billion, with net sales of $383.64 million and a net profit of -$59.73 million over the last four quarters. Shareholder's funds are $691.16 million, and total assets amount to $1.34 billion.

As of Jun 18, Innoviva, Inc. has a market capitalization of 2,032.09 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 383.64 million, while the sum of net profit for the same period is -59.73 million.<BR><BR>As of Dec 24, the reporting period shows shareholder's funds at 691.16 million and total assets at 1,335.48 million.

What does Innoviva, Inc. do?

Innoviva, Inc. develops and manages bio-pharmaceuticals, primarily focusing on respiratory treatments. As of March 2025, it reported net sales of $92 million and a net loss of $47 million, with a market cap of approximately $2.03 billion.

Overview:<BR>Innoviva, Inc. is engaged in the development, commercialization, and financial management of bio-pharmaceuticals, focusing on respiratory assets in the Pharmaceuticals & Biotechnology industry.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 92 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -47 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 2,032.09 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 15.00 <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.01 <BR>Return on Equity: 20.43% <BR>Price to Book: 3.14<BR><BR>Contact Details:<BR>Address: 2000 Sierra Point Pkwy Ste 500, BRISBANE CA: 94005-1830 <BR>Tel: 1 650 2389600 <BR>Website: https://www.inva.com/

Should I buy, sell or hold Innoviva, Inc.?

Who are in the management team of Innoviva, Inc.?

As of March 2022, the management team of Innoviva, Inc. includes Dr. Odysseas Kostas (Independent Chairman), and Independent Directors Mr. George Bickerstaff, Mr. Mark DiPaolo, Mr. Jules Haimovitz, and Dr. Sarah Schlesinger. They guide the company's strategic direction.

As of March 2022, the management team of Innoviva, Inc. includes the following members:<BR><BR>- Dr. Odysseas Kostas, who serves as the Independent Chairman of the Board.<BR>- Mr. George Bickerstaff, who is an Independent Director.<BR>- Mr. Mark DiPaolo, also an Independent Director.<BR>- Mr. Jules Haimovitz, serving as an Independent Director.<BR>- Dr. Sarah Schlesinger, who is another Independent Director. <BR><BR>This team is responsible for guiding the strategic direction of the company.

Is Innoviva, Inc. technically bullish or bearish?

As of September 19, 2025, Innoviva, Inc. shows a bearish trend with key indicators signaling caution, as it has underperformed against the S&P 500 recently.

As of 19 September 2025, the technical trend for Innoviva, Inc. has changed from mildly bullish to sideways. The current stance is bearish, with key indicators such as the MACD and KST both showing a mildly bearish signal on the weekly and monthly time frames. The Bollinger Bands indicate a bearish sentiment on the weekly chart, while the daily moving averages are mildly bullish, suggesting some short-term support. The stock has underperformed against the S&P 500 over the past week and month, with returns of -2.61% and -5.53% compared to the S&P's 1.22% and 3.95%, respectively. Overall, the technical indicators suggest a cautious outlook for Innoviva, Inc.

Is Innoviva, Inc. overvalued or undervalued?

As of October 17, 2025, Innoviva, Inc. is considered overvalued with a P/E ratio of 15, a low PEG ratio of 0.20, and has underperformed the S&P 500, suggesting it may not be a compelling investment compared to its peers.

As of 17 October 2025, the valuation grade for Innoviva, Inc. has moved from attractive to expensive, indicating a shift towards overvaluation. The company appears to be overvalued based on its current P/E ratio of 15, which is lower than the peer average of approximately 16.41, and an EV to EBITDA ratio of 9.21, which is also competitive compared to its peers. Additionally, the PEG ratio stands at a notably low 0.20, suggesting that the stock may not be justified at its current price level.<BR><BR>In comparison to its peers, MannKind Corp. has a significantly higher P/E ratio of 38.35, while Ligand Pharmaceuticals, Inc. shows a negative P/E of -67.27, highlighting the varying valuations within the industry. The stock has underperformed against the S&P 500 over multiple periods, with a 1-year return of -14.38% compared to the index's 14.08%, reinforcing the notion that Innoviva, Inc. may not be a compelling investment at this time.